A GWAS of OS is being conducted in order to understand the role that genetic variation plays in OS risk and to identify new genes or genomic regions that may be important in OS pathogenesis. National and international collaborations have been developed to facilitate accrual blood or buccal cell DNA on a large set of OS cases . Through the collaborative efforts of: The Children’s Oncology Group (COG); the Harvard School of Dental Medicine, Universidad de Navarra, Pamplona, Spain; Institut Curie, France; Rizzoli Instituti, Bologna, Italy; Royal Orthopaedic Hospital, London, UK; University of Toronto; Instituto de Oncologia Pediátrica GRAACC/UNIFESP; Ankara Oncology and Education Research Hospital, Ankara, Turkey; the Peter MacCallum Cancer Centre; and the Children’s Oncology Group study at the University of Minnesota, we estimate that approximately 3500 germline (blood or buccal cell) DNA samples of OS cases will be genotyped at the NCI's Cancer Genomics Research (CGR) Laboratory and subsequently available for GWAS analyses. A team of biostatisticians has been assembled to create a common control set that will be derived from existing studies. Follow-up will include genotyping and sequence analyses of genomic regions associated with OS. We will also investigate the newly identified genetic risk factors for clinical outcome.
Note: Genotype data from this study will be made available in dbGaP once the initial publication is in press at a peer-reviewed journal.